Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839240 · ClinicalTrials.gov registry record · Phase 1
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01839240 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 50 participants.
The verdict
NCT01839240, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of azacitidine when given together with cytarabine and mitoxantrone hydrochloride in treating patients with high-risk acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, cytarabine, and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also help cytarabine and mitoxantrone hydrochloride work better by making the cancer cells more sensitive to the drugs
Interventions
- OTHER laboratory biomarker analysis
- DRUG azacitidine
- DRUG cytarabine
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-06-06 |
| Est. Completion | 2019-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839240
The ClinicalTrials.gov registry entry for NCT01839240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01839240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839240 about?
NCT01839240 is a clinical study titled "Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia". This phase I trial studies the side effects and best dose of azacitidine when given together with cytarabine and mitoxantrone hydrochloride in treating patients with high-risk acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, cytarabine, and mitoxantrone hydrochloride, work in...
What is the current status of trial NCT01839240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2012-06-06. Estimated completion is 2019-08-16.
What interventions are being tested in trial NCT01839240?
The interventions under investigation include: laboratory biomarker analysis (OTHER), azacitidine (DRUG), cytarabine (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01839240?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.